Accelerate Diagnostics Announces First Quarter Financial Results and Provides COVID-19 Business Updates
TUCSON, Ariz., May 7, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced financial results for the quarter ending March 31, 2020 and provided a business update regarding the impact of the ongoing COVID-19 pandemic on the Company's operations.
"Our first quarter got off to a solid start, as sales, new contracts, and go-lives all progressed as anticipated through January and February. As we moved into March, hospitals began shifting their focus toward preparing for and treating COVID-19 patients, and these shifting priorities, along with meaningful restrictions on hospital access, led to lower-than-expected new contracts and go-lives for the quarter," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "However, we are adapting our business to maximize our commercial execution in the near term, and we will continue to work diligently on our longer-term initiatives to strengthen our commercial foundation and expand our portfolio of innovative, life-saving products."
2020 First Quarter Financial and Operational Highlights
-- Added 13 net new global commercially contracted instruments, including 21 new U.S. contracted instruments. -- Live U.S. Pheno instruments at the end of the first quarter were 197, with another 239 U.S. contracted Pheno instruments not yet live. -- Net sales for the first quarter of $2.3 million, compared to $1.8 million in the first quarter of 2019. -- Gross margin was 45% for the quarter, compared to 48% in the first quarter of 2019. -- Selling, general, and administrative expenses for the quarter were $12.9 million, compared to $12.7 million in the first quarter of 2019. -- Research and development (R&D) costs for the quarter were $5.8 million, compared to $6.9 million in the first quarter of 2019. -- Net loss was $21.3 million in the first quarter, or $0.39 per share, which included $4.2 million in non-cash stock-based compensation expense. -- Net cash used in the quarter was $16.4 million, and the Company ended the quarter with total cash, investments, and cash equivalents of $92.0 million. -- Entered into a commercial collaboration agreement with BioCheck, Inc., San Francisco, U.S., including their affiliate, Sophonix Ltd., Beijing, China, to sell serology-based SARS-COV-2 antibody tests (IgG and IgM) in the U.S. and EMEA, as disclosed in a press release dated April 14th, 2020.
Full financial results for the quarter ending March 31, 2020 will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
First Quarter 2020 Results Conference Call Information
The company will review full financial results for the first quarter of 2020 after the market close on Thursday, May 7, 2020. The company's management will host a conference call at 4:30 p.m. Eastern Time that same day to review the results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until August 7, 2020.
To listen by phone, dial +1.877.883.0383 and enter the conference ID: 8692081
International participants may dial +1.412.317.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using the replay code 10141855 until May 21, 2020.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as, among others, Mr. Phillips statements about adapting our business to maximize our commercial execution in the near term and our longer-term initiative to strengthen our commercial foundation and expand our portfolio of products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 27, 2020, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEET (in thousands, except share data) March 31, December 31, 2020 2019 Unaudited ASSETS Current assets: Cash and cash equivalents $ 39,487 $ 61,014 Investments 52,525 47,437 Trade accounts receivable 3,143 3,222 Inventory 8,527 8,059 Prepaid expenses 1,771 955 Other current assets 1,291 1,165 Total current assets 106,744 121,852 Property and equipment, net 8,639 7,905 Right of use assets 3,742 3,917 Other non-current assets 868 750 Total assets $ 119,993 $ 134,424 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,401 $ 2,351 Accrued liabilities 2,428 3,828 Accrued interest 191 1,262 Deferred revenue 186 271 Current operating lease liability 453 450 Total current liabilities 6,659 8,162 Non-current operating lease liability 3,466 3,579 Other non-current liabilities 93 19 Convertible notes 132,717 130,043 Total liabilities $ 142,935 $ 141,803 Commitments and contingencies Stockholders' deficit: Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and none outstanding as of March 31, 2020 and December 31, 2019 - Common stock, $0.001 par value; 85,000,000 common shares authorized December 31, 2019 with 54,993,588 shares issued and outstanding on March 31, 2020 and 85,000,000 common shares authorized with 54,708,792 shares issued and outstanding on 55 55 Contributed capital 457,987 452,344 Treasury stock (45,067) (45,067) Accumulated deficit (436,067) (414,653) Accumulated other comprehensive income (loss) 150 (58) Total stockholders' deficit (22,942) (7,379) Total liabilities and stockholders' deficit $ 119,993 $ 134,424
See accompanying notes to condensed consolidated financial statements.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Unaudited (in thousands, except per share data) Three Months Ended March 31, March 31, 2020 2019 Net sales $ 2,342 $ 1,750 Cost of sales 1,287 916 Gross profit 1,055 834 Costs and expenses: Research and development 5,842 6,933 Sales, general and administrative 12,943 12,723 Total costs and expenses 18,785 19,656 Loss from operations (17,730) (18,822) Other income (expense): Interest expense (3,749) (3,459) Foreign currency exchange loss (128) (59) Interest income 380 842 Other expense, net (82) (2) Total other expense, net (3,579) (2,678) Net loss before income taxes (21,309) (21,500) Provision for income taxes - (221) Net loss $ (21,309) $ (21,721) Basic and diluted net loss per share $ (0.39) $ (0.40) Weighted average shares outstanding 54,837 54,337 Other comprehensive loss: Net loss $ (21,309) $ (21,721) Net unrealized gain on debt securities available-for-sale 223 121 Foreign currency translation adjustment (15) (76) Comprehensive loss $ (21,101) $ (21,676)
See accompanying notes to condensed consolidated financial statements.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (in thousands) Three Months Ended March 31, March 31, 2020 2019 Cash flows from operating activities: Net loss $ (21,309) $ (21,721) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 755 626 Amortization of investment discount (4) (180) Equity-based compensation 4,199 3,397 Provision for bad debt expense 8 Amortization of debt discount and issuance costs 2,674 2,387 Unrealized loss on equity investments 8 Realized loss (gain) on sale of investments 3 (2) Loss on disposal of property and equipment 432 329 (Increase) decrease in assets: Accounts receivable (9) (90) Inventory (1,735) (1,567) Prepaid expense and other (1,030) (1,041) Increase (decrease) in liabilities: Accounts payable 968 1,151 Accrued liabilities, and other (1,475) (1,790) Accrued interest (1,071) (1,071) Deferred revenue and income (85) 74 Deferred compensation 74 (7) Net cash used in operating activities (17,597) (19,505) Cash flows from investing activities: Purchases of equipment (438) (37) Purchase of marketable securities (21,582) (12,826) Proceeds from sales of marketable securities - 9,000 Maturities of marketable securities 16,664 28,662 Net cash (used in) provided by investing activities (5,356) 24,799 Cash flows from financing activities: Proceeds from issuance of common stock 111 139 Proceeds from exercise of options 1,318 3,677 Net cash provided by financing activities 1,429 3,816 Effect of exchange rate on cash (3) (61) (Decrease) increase in cash and cash equivalents (21,527) 9,049 Cash and cash equivalents, beginning of period 61,014 66,260 Cash and cash equivalents, end of period $ 39,487 $ 75,309
See accompanying notes to condensed consolidated financial statements.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) Unaudited (in thousands) Three Months Ended March 31, March 31, 2020 2019 Non-cash investing activities: Transfer of instruments from inventory to property and equipment $ 1,282 $ 769 Supplemental cash flow information: Interest paid $ 2,144 $ 2,144 Income taxes paid, net of refunds $ 26 $ 2
See accompanying notes to condensed consolidated financial statements.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Unaudited (in thousands) Three Months Ended March 31, 2020 2019 Common stock shares outstanding Beginning 54,709 54,232 Exercise of options 270 215 Issuance of common stock under employee purchase plan 15 7 Ending 54,994 54,454 Common stock Beginning $ 55 $ 54 Ending $ 55 $ 54 Contributed capital Beginning $ 452,344 $ 432,885 Exercise of options 1,318 3,677 Issuance of common stock under employee purchase plan 111 139 Equity based compensation 4,214 3,453 Ending $ 457,987 $ 440,154
See accompanying notes to consolidated financial statements.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (CONTINUED) Unaudited (in thousands) Three Months Ended March 31, 2020 2019 Accumulated deficit Beginning $ (414,653) $ (330,348) Cumulative effect of accounting changes (105) Net loss (21,309) (21,721) Ending $ (436,067) $ (352,069) Treasury stock Beginning $ (45,067) $ (45,067) Ending $ (45,067) $ (45,067) Accumulated other comprehensive (loss) income Beginning $ (58) $ (149) Net unrealized gain on debt securities available-for-sale 223 121 Foreign currency translation adjustment (15) (76) Ending $ 150 $ (104) Total stockholders' (deficit) $ (22,942) $ 42,968
See accompanying notes to consolidated financial statements.
View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-announces-first-quarter-financial-results-and-provides-covid-19-business-updates-301055247.html
SOURCE Accelerate Diagnostics, Inc.